Tue. Sep 27th, 2022
Metachromatic Leukodystrophy Pipeline Analysis

As per DelveInsight’s assessment, globally, about 6+ key pharma and biotech companies are working on 6+ pipeline drugs in the Metachromatic Leukodystrophy (MLD) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Metachromatic Leukodystrophy (MLD) Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Metachromatic Leukodystrophy Therapeutics Market. 

The report provides a detailed description of the emerging drugs, including their type, stage, Mechanism of Action (MoA), Route of Administration (RoA), molecule type, inactive pipeline products, and NDA approvals. 

The report also covers in-depth commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed phase. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Metachromatic Leukodystrophy (MLD) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies in the Metachromatic Leukodystrophy Market.
  • It accesses the different therapeutic candidates segmented into early-stage (phase I), mid-stage (phase II), and late-stage (phase III) development. 
  • It assesses the targeted drug therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metachromatic Leukodystrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. 

Key Developments in the Metachromatic Leukodystrophy (MLD) Therapeutics Market

On June 08, 2022, Passage Bio, Inc. (Nasdaq: PASG) announced clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PBML04, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of Metachromatic Leukodystrophy (MLD).

DelveInsight’s Report covers around 6+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Metachromatic Leukodystrophy Therapeutic Segment:


Metachromatic Leukodystrophy (MLD) Therapeutics Analysis 

There are approx. 6+ key companies which are developing Metachromatic Leukodystrophy. Currently, Orchard Therapeutics has its Metachromatic Leukodystrophy drug candidates in the most advanced stage of clinical development.

Metachromatic Leukodystrophy (MLD) Emerging Drugs Covered in the report include:

  • OTL-200: Orchard Therapeutics
  • TAK-611: Takeda
  • MGTA-456

And many more

Some of the key companies in the Metachromatic Leukodystrophy (MLD) Therapeutics Market include:

  • Takeda
  • Denali Therapeutics
  • Orchard Therapeutics
  • Homology Medicines
  • Passage Bio
  • ArmaGen Technologies
  • Magenta Therapeutics

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:


Table of Content

  1. Report Introduction
  2. Executive Summary
  3. Metachromatic Leukodystrophy Current Treatment Patterns
  4. Metachromatic Leukodystrophy – DelveInsight’s Analytical Perspective
  5. Therapeutic Assessment
  6. Metachromatic Leukodystrophy Late Stage Products (Phase-III)
  7. Metachromatic Leukodystrophy Mid-Stage Products (Phase-II)
  8. Early Stage Products (Phase-I)
  9. Pre-clinical Products and Discovery Stage Products
  10. Inactive Products
  11. Dormant Products
  12. Metachromatic Leukodystrophy Discontinued Products
  13. Metachromatic Leukodystrophy Product Profiles
  14. Metachromatic Leukodystrophy Key Companies
  15. Metachromatic Leukodystrophy Key Products
  16. Dormant and Discontinued Products
  17. Metachromatic Leukodystrophy Unmet Needs
  18. Metachromatic Leukodystrophy Future Perspectives
  19. Metachromatic Leukodystrophy Analyst Review  
  20. Appendix
  21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Contact Info:
Anuj Rawat
Email: [email protected]
Request for Sample Copy of the Report at:

Other Trending Healthcare Reports By DelveInsight

Metachromatic Leukodystrophy (MLD) Market Insight

“Metachromatic Leukodystrophy (MLD) Market Insights, Epidemiology and Market Forecast” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Metachromatic Leukodystrophy (MLD) market size and shares analysis in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Metachromatic Leukodystrophy (MLD) Epidemiology Forecast

“Metachromatic Leukodystrophy (MLD) Epidemiology Forecast” report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Metachromatic Leukodystrophy (MLD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

By krehani

Leave a Reply

Your email address will not be published. Required fields are marked *